QURENasdaqPharmaceutical PreparationsFiscal year ends December 31
uniQure N.V.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$22.20+0.42 (+1.93%)
Close on Oct 19, 2026
- Market cap
- $1.47B
- P/E (TTM)
- –
- Dividend yield
- –
uniQure N.V. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Collaboration revenues | – | – | $164.00K | – | – | – | $10.87M | $11.58M | $11.97M | $5.16M | $2.25M | $2.30M | – | – |
| License revenues | – | – | $15.93M | $15.36M | $13.89M | $10.50M | $10.13M | $6.65M | $5.04M | $3.96M | $2.76M | $101.29M | – | – |
| Contract manufacturing revenues | – | – | – | – | – | – | $6.11M | $10.35M | $10.70M | $9.89M | $10.84M | – | – | – |
By region
From the segment and revenue-disaggregation notes of uniQure's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.